Onabotulinum toxin a (Botox®) in the treatment of neurogenic bladder overactivity

Nephro-Urology Monthly

Volumn 4, Issue 2, 2012, Pages 437-442

  Rohrsted, Malene ^a   Nordsten, Cecilie Bagi ^a   Bagi, Per ^a  

^a Rigshospitalet   (Denmark)

Author keywords

Neurogenic; Onabotulinumtoxin A urinary bladder; Overactive urinary bladder

Indexed keywords

ABOBOTULINUM TOXIN A; AMINOGLYCOSIDE; BOTULINUM TOXIN; BOTULINUM TOXIN A; BOTULINUM TOXIN B; CHOLINERGIC RECEPTOR BLOCKING AGENT; MUSCARINIC RECEPTOR BLOCKING AGENT; PLACEBO; TOXIN ANTIBODY; UNCLASSIFIED DRUG;

AUTONOMIC DYSFUNCTION; AUTONOMIC DYSREFLEXIA; BLADDER CATHETERIZATION; BLEPHAROSPASM; BLOOD BRAIN BARRIER; BOTULISM; CENTRAL NERVOUS SYSTEM DISEASE; DETRUSOR DYSSYNERGIA; DETRUSOR MUSCLE; DISEASE SEVERITY; DOSE TIME EFFECT RELATION; DRUG ACTIVITY; DRUG BINDING; DRUG CHOICE; DRUG CONTRAINDICATION; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG FORMULATION; DRUG INDICATION; DRUG MEGADOSE; DRUG POTENTIATION; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FLU LIKE SYNDROME; HEMATURIA; HUMAN; IDIOPATHIC DISEASE; INJECTION; INJECTION SITE PAIN; INTERMITTENT CATHETERIZATION; KIDNEY FAILURE; LOW DRUG DOSE; MALAISE; MOLECULAR SIZE; MOTOR DYSFUNCTION; MUSCLE WEAKNESS; NEUROGENIC BLADDER; NEUROGENIC DETRUSSOR OVERACTIVITY; NEUROMODULATION; NOCTURIA; NONHUMAN; OVERACTIVE BLADDER; PAIN; PARESIS; PATHOPHYSIOLOGY; PATIENT COMPLIANCE; POSTVOID RESIDUAL URINE VOLUME; PREGNANCY; QUALITY OF LIFE; REVIEW; RISK REDUCTION; SENSORY DYSFUNCTION; SIDE EFFECT; STRABISMUS; UNSPECIFIED SIDE EFFECT; URGE INCONTINENCE; URINARY TRACT DISEASE; URINARY TRACT INFECTION; URINE INCONTINENCE; URODYNAMICS; XEROSTOMIA;

EID: 84858410807     PISSN: 22517006     EISSN: 22517014     Source Type: Journal    
DOI: 10.5812/numonthly.1864     Document Type: Review

References (38)

1. Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U, et al. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn. 2002;21(2):167-78.
2. Drake MJ. Emerging drugs for treatment of overactive bladder and detrusor overactivity. Expert Opin Emerg Drugs. 2008;13(3):431-46.
3. Rapp DE, Lucioni A, Bales GT. Botulinum toxin injection: a review of injection principles and protocols. Int Braz J Urol. 2007;33(2):132-41.
4. Neel KF, Soliman S, Salem M, Seida M, Al-Hazmi H, Khatab A. Botulinum-A toxin: solo treatment for neuropathic noncompliant bladder. J Urol. 2007;178(6):2593-7; discussion 7-8
5. Hanchanale VS, Rao AR, Martin FL, Matanhelia SS. The unusual history and the urological applications of botulinum neurotoxin. Urol Int. 2010;85(2):125-30.
6. de Paiva A, Meunier FA, Molgo J, Aoki KR, Dolly JO. Functional repair of motor endplates after botulinum neurotoxin type A poisoning: biphasic switch of synaptic activity between nerve sprouts and their parent terminals. Proc Natl Acad Sci U S A. 1999;96(6):3200-5.
7. Bagi P, Biering-Sorensen F. Botulinum toxin A for treatment of neurogenic detrusor overactivity and incontinence in patients with spinal cord lesions. Scand J Urol Nephrol. 2004;38(6):495-8.
8. Scott AB. Development of botulinum toxin therapy. Dermatol Clin. 2004;22(2):131-3, v.
9. Erbguth FJ, Naumann M. Historical aspects of botulinum toxin: Justinus Kerner (1786-1862) and the "sausage poison". Neurology. 1999;53(8):1850-3.
10. Kroll P, Jankowski A, Soltysiak J, Murias M, Skrzypczak M, Zachwieja J. Botulinum toxin-A injections in children with neurogenic bladder. Nephro-Urol Mon. 2011;3(2):125-8.
11. Dressler D, Benecke R. Pharmacology of therapeutic botulinum toxin preparations. Disabil Rehabil. 2007;29(23):1761-8.
12. Leippold T, Reitz A, Schurch B. Botulinum toxin as a new therapy option for voiding disorders: current state of the art. Eur Urol. 2003;44(2):165-74.
13. Apostolidis A, Dasgupta P, Denys P, Elneil S, Fowler CJ, Giannantoni A, et al. Recommendations on the use of botulinum toxin in the treatment of lower urinary tract disorders and pelvic floor dysfunctions: a European consensus report. Eur Urol. 2009;55(1):100-19.
14. Lange DJ, Brin MF, Warner CL, Fahn S, Lovelace RE. Distant effects of local injection of botulinum toxin. Muscle Nerve. 1987;10(6):552-5.
15. Olney RK, Aminoff MJ, Gelb DJ, Lowenstein DH. Neuromuscular effects distant from the site of botulinum neurotoxin injection. Neurology. 1988;38(11):1780-3.
16. Canal N, Frattola L, Smirne S. The metabolism of cyclic-3'-5'-ad-enosine monophosphate (cAMP) in diseased muscle. J Neurol. 1975;208(4):259-65.
17. Dressler D, Benecke R. Autonomic side effects of botulinum toxin type B treatment of cervical dystonia and hyperhidrosis. Eur Neurol. 2003;49(1):34-8.
18. Dressler D. Dysport produces intrinsically more swallowing problems than Botox: unexpected results from a conversion factor study in cervical dystonia. J Neurol Neurosurg Psychiatry. 2002;73(5):604; author reply
19. Albanese A. Terminology for preparations of botulinum neurotoxins: what a difference a name makes. JAMA. 2011;305(1):89-90.
20. Naumann M, Carruthers A, Carruthers J, Aurora SK, Zafonte R, Abu-Shakra S, et al. Meta-analysis of neutralizing antibody conversion with onabotulinumtoxinA (BOTOX(R)) across multiple indications. Mov Disord. 2010;25(13):2211-8.
21. Dressler D, Eleopra R. Clinical use of non-A botulinum toxins: botulinum toxin type B. Neurotox Res. 2006;9(2-3):121-5.
22. Wyndaele JJ, Van Dromme SA. Muscular weakness as side effect of botulinum toxin injection for neurogenic detrusor overactivity. Spinal Cord. 2002;40(11):599-600.
23. McGuire EJ, Woodside JR, Borden TA, Weiss RM. Prognostic value of urodynamic testing in myelodysplastic patients. J Urol. 1981;126(2):205-9.
24. Wein A. Pathophysiology and classification of voiding dysfunction. In: Wein A, Kavoussi L, Novick A, Partin A, Peters C, editors. Campbell-Walsh Urology Ninth ed. Philadelphia, PA: Saunders/ Elsevier; 2007.
25. Dykstra DD, Sidi AA, Scott AB, Pagel JM, Goldish GD. Effects of botulinum A toxin on detrusor-sphincter dyssynergia in spinal cord injury patients. J Urol. 1988;139(5):919-22.
26. Schurch B, de Seze M, Denys P, Chartier-Kastler E, Haab F, Everaert K, et al. Botulinum toxin type a is a safe and effective treatment for neurogenic urinary incontinence: results of a single treatment, randomized, placebo controlled 6-month study. J Urol. 2005;174(1):196-200.
27. Kuo HC. Will suburothelial injection of small dose of botulinum A toxin have similar therapeutic effects and less adverse events for refractory detrusor overactivity? Urology. 2006;68(5):993-7; discussion 7-8.
28. Schurch B, Stohrer M, Kramer G, Schmid DM, Gaul G, Hauri D. Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: a new alternative to anticholinergic drugs? Preliminary results. J Urol. 2000;164(3 Pt 1):692-7.
29. Karsenty G, Denys P, Amarenco G, De Seze M, Game X, Haab F, et al. Botulinum toxin A (Botox) intradetrusor injections in adults with neurogenic detrusor overactivity/neurogenic overactive bladder: a systematic literature review. Eur Urol. 2008;53(2):275-87.
30. Kalsi V, Gonzales G, Popat R, Apostolidis A, Elneil S, Dasgupta P, et al. Botulinum injections for the treatment of bladder symptoms of multiple sclerosis. Ann Neurol. 2007;62(5):452-7.
31. Game X, Mouracade P, Chartier-Kastler E, Viehweger E, Moog R, Amarenco G, et al. Botulinum toxin-A (Botox) intradetrusor injections in children with neurogenic detrusor overactivity/ neurogenic overactive bladder: a systematic literature review. J Pediatr Urol. 2009;5(3):156-64.
32. Reitz A, Schurch B. Intravesical therapy options for neurogenic detrusor overactivity. Spinal Cord. 2004;42(5):267-72.
33. Abdel-Meguid TA. Botulinum toxin-A injections into neurogenic overactive bladder -to include or exclude the trigone?: a prospective, randomized, controlled trial. J Urol. 2010;184(6):2423-8.
34. Lucioni A, Rapp DE, Gong EM, Fedunok P, Bales GT. Intravesical botulinum type A toxin injection in patients with overactive bladder: trigone versus trigone-sparing injection. Can J Urol. 2006;13(5):3291-5.
35. Cruz F, Herschorn S, Aliotta P, Brin M, Thompson C, Lam W, et al. Efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: a randomized, double-blind, placebo-controlled trial. European Urology. 2011:[Epub ahead of print].
36. Comperat E, Reitz A, Delcourt A, Capron F, Denys P, Chartier-Kastler E. Histologic features in the urinary bladder wall affected from neurogenic overactivity:a comparison of inflammation, oedema and fibrosis with and without injection of botulinum toxin type A. Eur Urol. 2006;50(5):1058-64.
37. Reitz A, Denys P, Fermanian C, Schurch B, Comperat E, Chartier-Kastler E. Do repeat intradetrusor botulinum toxin type a injections yield valuable results? Clinical and urodynamic results after five injections in patients with neurogenic detrusor overactivity. Eur Urol. 2007;52(6):1729-35.
38. Dowson C, Khan MS, Dasgupta P, Sahai A. Repeat botulinum toxin-A injections for treatment of adult detrusor overactivity. Nat Rev Urol. 2010;7(12):661-7.